Centre for Amyloidosis and Acute Phase Proteins
- About Us
- National Amyloidosis Centre
- Amyloidosis Overview
- Information for Patients
- Information for Referring Physicians
- Fever Syndromes
- Molecular Genetic Testing
- The Registry for Mutations and Phenotypes in Hereditary Amyloidosis
- Clinical Research at the National Amyloidosis Centre
- Patient Information Leaflets
- Public and Patient Involvement
- Comprehensive Patient Information Website
- Support Us
- Key Publications
- Contact Us
- Home - Division of Medicine
The periodic fever syndromes are recurring episodes of fever and inflammation (which can be very painful), affecting the abdomen, chest, joints, skin and/or eyes. The inherited diseases (described below) usually present in childhood as does another disease of uncertain cause called PFAPA syndrome. Some of these diseases can also present in adults and Schnizler’s syndrome (also described below) seems to only affect older adults.
similarities in their symptoms, they have differing causes, patterns of inheritance,
length and frequency of ‘attacks’. Many
of these diseases can now be very effectively treated.
Familial Mediterranean fever (FMF)
Familial Mediterranean fever (FMF) is the commonest of the inherited fever syndromes. It is most often seen in people of Middle Eastern ancestry but can occur in other populations too. It affects both sexes equally and the symptoms usually start in childhood. The disease is thought to affect 1/250 to 1/500 in Sephardic Jews and 1/1,000 in the Turkish population.
The cause of FMF is abnormalities in a gene called MEFV. FMF is a recessive disease meaning that about 85% of patients with FMF have changes (a mutation) in both copies of their MEFV gene. Although 14-25% of patients with a clinical diagnosis of FMF have only one identified mutation, the great majority of individuals with a single mutation are completely healthy carriers. In fact as many as 1 in 4 healthy people in some eastern Mediterranean populations carry an MEFV mutation. This has led to the suggestion that FMF carriers may have had an advantage in the past, possibly that they were less vulnerable to infections.
We are aware of more than 80 different changes (mutations) in MEFV that can cause the disease. Disease causing mutations mostly occur in the part of the gene called exon 10, but we can also find changes in exons 1, 2, 3, 5, 8 and 9.
Attacks of FMF occur irregularly although some people find that minor physical or emotional stress, the menstrual cycle or changes in their diet can cause attacks. Attacks usually last 1 to 3 days with fever and other symptoms. Severe abdominal pain occurs in 85% of cases. Pain which is worse on deep breathing or coughing occurs in 40% of patients, usually only affecting one side of the chest. Severe headache occurs particularly in children, and rarely, in young boys, there can be pain and swelling of the testicles. Muscle and joint pain is common but long term joint damage is very rare. 20% of affected children have muscle pain on exertion, usually affecting the calves even between attacks. A characteristic rash occurs in 20% of patients, usually around the ankles.
Attacks are accompanied by blood test abnormalities showing inflammation, including high white cells, and a very high C-reactive protein (CRP). Investigations may be required to exclude other causes of fever and pain but X-ray, ultrasound or echocardiography during FMF attacks are usually unremarkable.
The diagnosis is supported by gene testing but relies on the history of recurrent short attacks of fever and pain which are accompanied by abnormal blood tests and that are prevented by long term colchicine.
The mainstay of management is long term treatment with
low doses of a tablet called colchicine. Continuous treatment with colchicine prevents
or substantially reduces symptoms of FMF in at least 95%. How colchicine works remains incompletely
understood. Long-term colchicine is advisable in every patient with FMF and vital
in those who have AA amyloidosis. Although
colchicine is very toxic in acute overdose, the low daily doses required for
treatment of FMF are generally very well tolerated by children and adults.
Diarrhoea is the most common side effect and can usually be avoided by gradual
introduction of the drug and, if necessary, temporary withdrawal of milk products
from the diet. Despite theoretical concerns, there is no evidence that colchicine
causes infertility or birth defects, and it can be taken safely by nursing
mothers. Colchicine has now been licensed by the US Food and Drug
administration for the treatment of FMF from the age of 4 years upwards.
Tumour necrosis factor receptor associated periodic syndrome (TRAPS)
Tumour necrosis factor receptor associated periodic syndrome (TRAPS) is very rare and affects about 1 person in a million in Europe. It is an autosomal dominant disease associated with mutations in tumour necrosis factor receptor superfamily 1A gene(TNFRSF1A). As only one abnormal copy of the gene is required to cause disease many patients have family members who also have the disease.
TRAPS was described in 1982 as familial Hibernian fever, but TRAPS has been reported in many ethnic groups. Both sexes are equally affected and symptoms usually start before the age of 4 years. TRAPS attacks are often far less distinct than in FMF. Fever episodes last for weeks and symptoms are near continuous in a third of patients. More than 95% of patients experience fever, and 80% have limb pains that may slowly move inwards towards the chest or abdomen; abdominal pain occurs in 80%, and rash occur in 70% of patients. Other features of attacks include headache, chest pain, enlarged glands and red and swollen eyes. Attacks are accompanied by blood test abnormalities showing inflammation, including high white cells, and a very high C-reactive protein (CRP). Genetic testing is necessary to making a diagnosis.
Acute attacks can be stopped by high dose corticosteroids
but this does not stop further attacks from occurring. In more severe disease
long term treatment with injected drugs, which block some of the messengers of
inflammation, can be very effective in preventing attacks.
Mevalonate kinase deficiency (MKD)
Mevalonate kinase deficiency (MKD), also known as Hyperimmunoglobulin D and periodic fever syndrome (HIDS), is an autosomal recessive disease caused by mutations in the mevalonate kinase (MVK) gene. About 60 different mutations have been described and most patients will have a change in both copies of their gene.
MKD is extremely rare and is most often seen in people from North Western Europe. The disease occurs equally in both sexes and usually starts in the first year of life. Attacks are irregular, typically lasting three to seven days, and can be provoked by vaccination, minor trauma, surgery or stress. Symptoms during attacks include fever, enlarged gland in the neck and abdominal pain with vomiting and diarrhoea. Headache, aching limbs, large joint arthritis, rash and mouth ulcers are also common. Attacks are accompanied by blood test abnormalities showing inflammation, including high white cells, and a very high C-reactive protein (CRP).
is largely aimed at controlling the fever, pain and sickness during attacks but
long term treatment with injected drugs, which block the messengers of
inflammation, can be very effective in preventing attacks.
Cryopyrin associated periodic syndrome (CAPS)
Most reported patients with cryopyrin associated periodic syndrome (CAPS) have European ancestry but cases have been described from South Asia and elsewhere. The disease usually starts in early infancy, often from birth. Milder disease is typically recurrent episodes of fever, limb aching, red eyes and rash brought on by cold or wet weather. In mid severity disease attacks of fever, aching, non-itchy urticarial rash (looks a bit like ‘nettle rash’) and often headache occur every day, usually from the afternoon onwards. Up to 40% of these patients will develop deafness. The most severe form of CAPS is known as CINCA (chronic infantile neurological, cutaneous and articular syndrome) or NOMID (neonatal onset multisystem inflammatory disease). This is a very severe inflammatory disorder that presents soon after birth. Along with the other features of CAPS there is often destruction of joints and inflammation of the lining of the brain resulting in brain damage, blindness and deafness.
CAPS is caused by mutations in the NLRP3/CIAS1 gene. The disease is dominant and about 75% of patients with milder disease have affected relatives. CINCA, at the most severe end of the clinical spectrum, is usually due to new mutations and there are usually no affected relatives.
Attacks are accompanied by blood test abnormalities showing inflammation, including high white cells, and a very high C-reactive protein (CRP).
There is now very successful treatment for CAPS but
this has to be given as injection of drugs which block the messenger of
inflammation called IL-1. We run the national treatment centre for CAPS using
canakinumab a drug that blocks IL-1 and has to be injected under the skin every
8 weeks. We hope that early treatment may prevent development of complications
of CAPS such as deafness and eye damage.
The following diseases are very rare with only a few families known in the world
Deficiency of the IL-1 receptor antagonist (DIRA)
This disease was first described in 2009. It is due to mutations in the IL1RN gene and begins immediately after birth with a rash, joint swelling, and bony swellings in the ribs and the long bones of the arms and legs. It responds very well to treatment with injected drugs.
Pyogenic sterile arthritis, pyoderma gangrenosum and acne (PAPA) syndrome
This exceptionally rare disease is caused by mutations in the PTSTPIP gene. It causes severe acne and recurrent joint swelling typically after minor knocks or damage. Early reports suggest that injected therapies may be effective.
This causes rash, joint damage and eye inflammation. Treatment is usually with corticosteroids. It is caused by mutations in NOD2/CARD15.
Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA)
This was first described in 1987 in a dozen otherwise healthy children. The diagnosis is suggested by the presence of a recurrent fever before the age of 5 years and at least one of the following: mouth ulcers, enlarged glands in the neck or a sore red throat, without an infection. Children are entirely well between attacks and their parents frequently report that they seem less susceptible than other children to minor viral infections. Boys are slightly more affected than girls and it may be commoner among those of European ancestry. The diagnosis is clinical and there is no special test for PFAPA. Attacks are accompanied by blood test abnormalities showing inflammation, including high white cells, and a very high C-reactive protein (CRP). In general most children will outgrow their symptoms within a decade.
Features which suggest a diagnosis of PFAPA are extremely regular and predictable attacks (although there may be some skipping of attacks, particularly in the summer months) and the response to a small dose of corticosteroids. The first line treatment of PFAPA is a single dose of corticosteroid given at the start of the attack. Colchicine has been tried in PFAPA with variable reports of success but our experience has been favourable and it is our first choice of drug. In some children removing their tonsils can stop the attacks completely.
This adult disease causes a chronic urticarial rash (looks a bit like ‘nettle rash’), fatigue and fever. It usually starts around the age of 50 years or older. Affected patients have an underlying minor bone marrow disease and their plasma cells make too much of an antibody protein, called IgM. This appears to be the cause of Schnitzler’s syndrome although exactly how is not yet clear. Chemotherapy treatment of the bone marrow is not helpful in stopping the rash and fever, although about a fifth of patients eventually develop cancerous bone marrow disease that needs treatment in its own right and may require chemotherapy then.
The treatment of choice of Schnitzler’s syndrome is injected
drugs which block a messenger of inflammation called IL-1 and completely
prevents all the symptoms.
Long term outcomes
Although CINCA/NOMID and DIRA can be
sufficiently severe to cause death within the first few decades, life
expectancy among many patients with autoinflammatory disorders is good, and is
expected to be excellent in those for whom there is now effective therapy. Most people on treatment will lead completely
normal lives. The most serious and life-threatening complication of these
diseases generally is AA amyloidosis (see amyloid information).
Page last modified on 14 nov 13 17:05 by E A ( Beth ) Jones